GNX 104 is a Phase II in-patient placebo-controlled monotherapy trial of the experimental anticonvulsant ganaxolone in adults with refractory partial epilepsy whose regular anti-convulsants have been discontinued during a routine hospital admission on 8 Long immediately preceding this study for EEG/video telemetry to determine their suitability for surgical treatment of seizures. The study will evaluate the safety, tolerability and efficacy of ganaxolone.
Showing the most recent 10 out of 634 publications